Latest Conference Articles

December 10th 2020, 12:26am

San Antonio Breast Cancer Symposium

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

December 9th 2020, 10:32pm

San Antonio Breast Cancer Symposium

Ian Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer

December 9th 2020, 10:05pm

San Antonio Breast Cancer Symposium

December 9, 2020 - The combination of oral paclitaxel and encequidar led to an estimated 26.5% reduction in the risk of death compared with intravenous paclitaxel in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.

December 9th 2020, 9:49pm

San Antonio Breast Cancer Symposium

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

December 9th 2020, 9:14pm

San Antonio Breast Cancer Symposium

December 9, 2020 - The artificial intelligence–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

December 9th 2020, 8:21pm

San Antonio Breast Cancer Symposium

December 9, 2020 - Intrinsic tumor subtype was found to be associated with prognosis in patients with hormone receptor–positive, HER2-negative advance breast cancer who received the CDK4/6 inhibitor ribociclib.

December 9th 2020, 2:50pm

San Antonio Breast Cancer Symposium

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

December 9, 2020 - Follow-up circulating tumor cell assessments were confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer, when performed at a median of 29 days following treatment initiation.

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

December 8, 2020 - Oncologists widely under-recognize substantial symptoms in patients with breast cancer receiving radiotherapy after undergoing a lumpectomy, highlighting a need to improve symptom detection.

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

The addition of chemotherapy to endocrine therapy led to an improvement in 5-year invasive disease-free survival and overall survival in premenopausal but not postmenopausal women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

December 9th 2020, 1:59pm

ASH Annual Meeting and Exposition

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

December 8th 2020, 11:38pm

ASH Annual Meeting and Exposition

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

December 8th 2020, 11:33pm

ASH Annual Meeting and Exposition

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

December 8th 2020, 10:24pm

ASH Annual Meeting and Exposition

The antibody-drug conjugate TRPH-222 demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

December 8th 2020, 9:37pm

ASH Annual Meeting and Exposition

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

December 8th 2020, 6:16pm

ASH Annual Meeting and Exposition

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

December 8th 2020, 6:00pm

ASH Annual Meeting and Exposition

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

December 8th 2020, 5:37pm

ASH Annual Meeting and Exposition

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

December 8th 2020, 3:00pm

ASH Annual Meeting and Exposition

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.